MiMedx - MDXG Total Company Value-to-Revenue Ratio

mimedx.com (MDXG) - corporate logo

MiMedx Group, Inc. (MDXG) develops biomaterials for tissue regeneration, ensuring high margins and free cash flow. Its independence from macroeconomic trends makes the asset defensive. The EV/Sales trajectory visualizes these business proportions, where the current status equals 1096.50. Leadership in the placental drug niche allows the company to exercise pricing power over insurance companies for effective wound treatment.

MDXG MiMedx Group, Inc.: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/20/2026

MiMedx Corp - analytical breakdowns and key metrics (MDXG)

Initial company analysis:MiMedx Group, Inc.
Manufactured product of MiMedx Group

A defensive portfolio is constructed through the strict selection of assets with sustainable fundamental value. This metric compares the total enterprise value, including debt, against annual sales volume, neutralizing the impact of the credit load. For MiMedx Group, Inc. (MDXG), dominance in the biologics niche and insurance support justify a premium multiple. The investor assesses the efficiency of revenue capitalization through historical EV/Sales trends, which allows for the determination of whether the asset is overbought.

Competitor analysis for MiMedx Group, Inc.

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|SLNO - Enterprise Value-to-Revenue Ratio|Amicus Pharma (FOLD) - Company Value to Revenue|ETNB: EV/Sales Multiple|AGIO - Total Company Value-to-Revenue Ratio|Company Value to Revenue GPCR|Enterprise Value-to-Revenue Multiple Rezolute Inc RZLT|EV/Sales Multiple LXRX|Total Company Value-to-Revenue Ratio MBX Corp|Altimmune Pharma - Company Value to Revenue|EV/Sales Multiple aardvarktherapeutics.com AARD|SGMT: Company Value to Revenue|Business Value to Revenue BIOA (BioAge Labs)|BMEA: EV/Sales Multiple|QNCX: Enterprise Value-to-Revenue Coefficient|GUTS (Fractyl Health, Inc.) - EV/Sales Multiple|EV/Sales Multiple vtvtherapeutics.com|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)